Research programme: zinc finger protein antagonists - Achillion
Alternative Names: ACH 100703; ACH 10076Latest Information Update: 05 Feb 2020
At a glance
- Originator Achillion Pharmaceuticals
- Developer Achillion Pharmaceuticals; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases
- Class
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 07 Oct 2002 Data presented at the 42nd Annual Meeting of the Interscience Conference on Anitmicrobial Agents and Chemotherapy (ICAAC-2002) have been added to the Viral Infections antimicrobial activity and pharmacodynamics sections
- 13 Jul 2001 Preclinical development for HIV infections treatment in USA (Unknown route)